PNTG Pennant Group, Inc.
Services-Health Services · Nasdaq · SEC CIK 1766400 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.7%
TTM net income YoY34.4%
TTM EPS YoY34.7%
Revenue 3-yr CAGR30.9%
Net income 3-yr CAGR42.1%
Margins
Gross margin18.3%
Operating margin5.8%
Net margin3.1%
FCF margin2.9%
EBITDA margin6.8%
Returns
ROE10.3%
ROA4.0%
ROIC (approx.)11.3%
Asset turnover1.31x
Leverage & solvency
Liabilities / assets59.7%
Debt / equity0.53x
Current ratio1.18x
Interest coverage5.15x
Cash quality & payout
Operating cash flow / net income1.80x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $947.71M | $695.24M |
| Cost of revenue | $768.50M | $558.45M |
| Gross profit | $179.20M | $136.79M |
| SG&A expense | $71.08M | $50.21M |
| Operating income | $51.89M | $38.12M |
| Interest expense | $6.68M | $6.96M |
| Pretax income | $45.63M | $31.37M |
| Income tax | $11.87M | $7.03M |
| Net income | $29.58M | $22.56M |
| EBITDA | $60.42M | $44.23M |
| EPS (basic) | 0.86 | 0.72 |
| EPS (diluted) | 0.84 | 0.70 |
| Weighted avg. shares (diluted) | 35.32M | 32.00M |
| Balance sheet | ||
| Cash & equivalents | $17.02M | $24.25M |
| Receivables | $123.11M | $81.30M |
| Current assets | $167.41M | $122.86M |
| PP&E, net | $60.98M | $43.30M |
| Goodwill | $237.25M | $129.12M |
| Total assets | $968.18M | $679.52M |
| Current liabilities | $147.26M | $101.70M |
| Short-term debt | $5.00M | $0 |
| Long-term debt | $168.84M | $0 |
| Total debt | $173.84M | $0 |
| Total liabilities | $593.93M | $367.56M |
| Shareholders' equity | $332.60M | $293.28M |
| Net debt | $156.81M | -$24.25M |
| Shares outstanding | 34.63M | 34.37M |
| Cash flow statement | ||
| Operating cash flow | $48.29M | $39.30M |
| Capital expenditure | $12.04M | $8.99M |
| Free cash flow | $36.26M | $30.31M |
| Investing cash flow | -$227.97M | -$70.68M |
| Financing cash flow | $172.46M | $49.57M |
| Depreciation & amortization | $8.54M | $6.12M |
| Stock-based compensation | $8.94M | $7.78M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.